Vir Biotechnology(NASDAQ) VIR

Vir Biotechnology makes medicines that help the immune system fight viruses and cancer. These treatments help people with chronic liver infections and various solid tumors. The company uses artificial intelligence to find and improve natural antibodies.

The Clinical Pipeline

• Hepatitis Delta Therapies: Tobevibart and elebsiran are tested together to treat chronic liver infections caused by the hepatitis delta virus.
• Cancer T-Cell Engagers: VIR-5500 and VIR-5818 guide the immune system to find and destroy tumor cells in prostate and other cancers.
• COVID-19 Antibodies: Sotrovimab is an authorized monoclonal antibody, which is a lab-made protein that acts like a natural antibody to fight infection.
• Hepatitis B Research: Investigational treatments use siRNA technology to block the specific genes that allow the hepatitis B virus to multiply.

Major Moves and Partnerships

• Partnered with Astellas US LLC in February 2026 to share development and sales costs for the prostate cancer treatment VIR-5500.
• Licensed commercial rights for liver disease treatments to Norgine Pharma UK Limited in December 2025 for markets in Europe and Australia.
• Acquired a global license for masking technology from Sanofi subsidiary Amunix Pharmaceuticals in September 2024 to improve drug safety.
• Updated a collaboration with Alnylam Pharmaceuticals in March 2025 to lead the development of specialized gene-blocking treatments for liver viruses.

What Sets the Tech Apart

Vir uses its dAIsY platform to combine data and artificial intelligence for optimizing antibodies to improve their performance. Its masking technology ensures cancer drugs only become active when they reach a tumor, which may reduce side effects for patients.

Measuring Financial Progress

• Revenue reached $64.1 million in Q4 2025, up 417.8% from $12.4 million in Q4 2024.
• Gross profit turned positive to $430.6 million in Q4 2025, up 663.5% from a loss of $76.4 million the previous year.
• Net loss narrowed to $42.9 million in Q4 2025, a 59% improvement compared to a $104.6 million loss in Q4 2024.
• Free cash flow was negative $21.4 million in Q4 2025, which narrowed 76.2% from negative $90 million in Q4 2024.

The Bottom Line

Vir has shifted from pandemic-focused antibody development toward a pipeline specializing in chronic liver disease and oncology. Its platform-based approach and corporate partnerships support its efforts to transform how the immune system handles complex diseases.